Travis Steed, an analyst from Bank of America Securities, reiterated the Hold rating on Haemonetics. The associated price target remains the same with $90.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Travis Steed has given his Hold rating due to a combination of factors that balance solid momentum in parts of Haemonetics’ business against lingering uncertainties in others. He sees the company broadly on track to deliver on the commitments laid out last November, with particular strength in the plasma segment, where collection volumes and share gains are running ahead of what management initially assumed. Because plasma is a higher-margin business, this outperformance is expected to provide meaningful support to overall profitability in the near term, even as weaker areas weigh on results.
At the same time, Steed is cautious about the pace of recovery in vascular closure, which now appears more like a fiscal 2027 story rather than a near-term driver. He notes that the second-half improvement implied in guidance may prove optimistic, amid slower market growth tied to evolving PFA technologies, fewer access points, and potential pricing and share pressure as more procedures shift to ambulatory settings. Given these moving parts and the need for clearer visibility into the IVT turnaround, he is reluctant to take a more aggressive stance, especially with the stock already trading at a mid-teens multiple of forward earnings. Accordingly, he maintains a Neutral (Hold) view while updating his model to reflect stronger plasma trends and a more drawn-out recovery in vascular closure.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HAE in relation to earlier this year.